Pharmacokinetics of escalating single-dose administration of cannabidiol to cats

doi: 10.1111/jvp.13100.

Online ahead of print.

Aaron J Rozental¹, Daniel L Gustafson¹, Breonna R Kusick¹, Lisa R Bartner¹, Stephanie Cruz Castro¹, Stephanie McGrath¹

Affiliations

PMID: 36300854
DOI: 10.1111/jvp.13100

Abstract

This study aimed to assess the single-dose pharmacokinetics and tolerability of a cannabidiol (CBD) isolate in sunflower oil with escalating oral doses in eight healthy, purpose-bred cats. Eight cats were randomized into six dosing groups of four cats each. Cats were administered a single 2.5, 5, 10, 20, 40, or 80 mg/kg dose orally with at least a two-week washout in between doses. Behavior scoring, complete blood count, serum biochemistry analysis, physical examination, and CBD plasma levels were evaluated before and after dosing. All cats successfully completed the study. CBD was measured in the plasma of all cats dosed with CBD oil. The Cmax and AUC increased in a dose-proportional fashion across all dosing groups. There were no major bloodwork or behavioral changes although the BUN and creatinine values decreased after treatment across all doses. No adverse effects were observed, and behavioral changes were limited to head shaking, lip smacking, and hypersalivation immediately following dose administration. Single orally administered CBD doses up to 80 mg/kg were safe and well tolerated in this cohort of cats and display dose-proportional pharmacokinetics across a broad concentration.

Keywords: cannabidiol, cannabinoid, cannabis, feline, pharmacokinetics

References

REFERENCES

1. Acierno, M. J., Brown, S., Coleman, A. E., Jepson, R. E., Papich, M., Stepien, R. L., & Syme, H. M. (2018). ACVIM consensus statement: Guidelines for the identification, evaluation, and management of systemic hypertension in dogs and cats. Journal of Veterinary Internal Medicine, 32(6), 1803-1822.
1. Bartner, L. R., McGrath, S., Rao, S., Hyatt, L. K., & Wittenburg, L. A. (2018). Pharmacokinetics of cannabidiol administered by 3 delivery methods at 2 different dosages to healthy dogs. Canadian Journal of Veterinary Research, 82(3), 178-183.
1. Birnbaum, A. K., Karanam, A., Marino, S. E., Barkley, C. M., Remmel, R. P., Roslawski, M., Gramling-Aden, M., & Leppik, I. E. (2019). Food effect on pharmacokinetics of cannabidiol oral capsules in adult patients with refractory epilepsy. Epilepsia, 60(8), 1586-1592. https://doi.org/10.1111/epi.16093
1. Brenneisen, R. (2007). Chemistry and analysis of phytocannabinoids and other cannabis constituents. In M. A. ElSohly (Ed.), Marijuana and the cannabinoids. Forensic science and medicine. Humana Press.
1. Brioschi, F. A., Di Cesare, F., Gioeni, D., Rabbogliatti, V., Ferrari, F., D’Urso, E. S., Amari, M., & Ravasio, G. (2020). Oral transmucosal cannabidiol oil formulation as part of a multimodal analgesic regimen: Effects on pain relief and quality of life improvement in dogs affected by spontaneous osteoarthritis. Animals (Basel), 10(9), 1505.